^
Association details:
Biomarker:TSC2 A736V
Cancer:Neurofibrosarcoma
Drug:everolimus (mTOR inhibitor)
Direction:Resistant
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Source:
Title:

Next generation sequencing of sarcomas: Response to crizotinib in two cases with MET amplification.

Published date:
05/19/2021
Excerpt:
Table summarizes matched therapies in responders....Malignant peripheral nerve sheath tumor...TSC2: A736V...Temsirolimus + cyclophosphamide + vinorelbine – PR, 13 mo. Everolimus - PD
DOI:
10.1200/JCO.2021.39.15_suppl.11538